ContraVir Pharmaceuticals (CTRV) Stock Rating Reaffirmed by Maxim Group

Retrieved on: 2018-04-14 19:03:45

Tags for this article:

Click the tags to see associated articles and topics

ContraVir Pharmaceuticals (CTRV) Stock Rating Reaffirmed by Maxim Group. View article details on hiswai:

Excerpt

<div>An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. <b>Vanguard Group</b> Inc. boosted its stake in ContraVir Pharmaceuticals (NASDAQ:CTRV) by 17.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).</div>

Article found on:

View Original Article